|
唐小川 倒在了黎明前。。。 KN026+KN046用于标准治疗失败的、HER2异常的晚期实体瘤 810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors https://jitc./content/8/Suppl_3/A861 339 Preliminary safety, tolerability and efficacy results of KN026 (a HER2-targeted Bispecific Antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in patients (pts) with HER2 aberrated solid tumors https://jitc./content/8/Suppl_3/A364 IBI188：1 mpk priming + 30 mpk maintenance 295 First-in-human Phase I trial of IBI188, an anti-CD47 targeting monoclonal antibody, in patients with advanced solid tumors and lymphomas https://jitc./content/8/Suppl_3/A322 385 A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results https://jitc./content/8/Suppl_3/A410 1-30mpk没有出现DLT，最常见的TRAE包括贫血30%、疲劳25%、IRR20%及腹泻15%，全部是1-2级。所有剂量组在首个疗程都能观察到瞬时的、非剂量相关的血红蛋白下降，均值1.5mg/dL。所有剂量组中没有观察到溶血性贫血。中高剂量组中单剂量的lemzoparlimab呈现线性，CD47靶点RO显示在≥20mpk的浓度峰值下实现保全饱和 384 A Phase 1 study to evaluate the safety, PK, and antitumor activity of AK117, an anti-CD47 monoclonal antibody, in subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas https://jitc./content/8/Suppl_3/A409 裤子都脱了啥也没看到 630 PD-L1/CD47 tumor directed B-BodyTM bispecific antibodies demonstrating significant anti-tumor activity with no toxicity in preclinical models https://jitc./content/8/Suppl_3/A666 Penpulimab 791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL) https://jitc./content/8/Suppl_3/A840 804 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy https://jitc./content/8/Suppl_3/A853
|
|
|
